Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies
出版年份 2020 全文链接
标题
Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 24, Pages 9492
出版商
MDPI AG
发表日期
2020-12-15
DOI
10.3390/ijms21249492
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Overcoming Radioresistance in Tumor Therapy by Alleviating Hypoxia and Using the HIF-1 Inhibitor
- (2020) Xingguo Zhou et al. ACS Applied Materials & Interfaces
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
- (2020) Denisa Baci et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF‐α pathway
- (2020) Shan Su et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial
- (2020) J.A. Ledermann et al. GYNECOLOGIC ONCOLOGY
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Epithelial ovarian cancer
- (2019) Stephanie Lheureux et al. LANCET
- Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer
- (2019) J F Liu et al. ANNALS OF ONCOLOGY
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Human recombinant FSH induces chemoresistance in human breast cancer cells via HIF-1α activation†
- (2019) L Bergandi et al. BIOLOGY OF REPRODUCTION
- The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond
- (2019) Silvia Pastorekova et al. CANCER AND METASTASIS REVIEWS
- Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints
- (2019) Audrey LEQUEUX et al. CANCER LETTERS
- Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
- (2019) Rowan E Miller et al. Future Oncology
- HIF inactivation of p53 in Ovarian Cancer Can be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity
- (2019) Basmina Parmakhtiar et al. MOLECULAR CANCER RESEARCH
- Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
- (2019) Benjamin D. Dickson et al. MOLECULES
- Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
- (2019) Alanna R. Kaplan et al. Science Translational Medicine
- Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
- (2019) Krishnansu S. Tewari et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of cancer-associated fibroblasts in tumor structure, composition and the microenvironment in ovarian cancer (Review)
- (2019) Wei Sun et al. Oncology Letters
- Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells
- (2019) Jinling Huang et al. MEDICAL SCIENCE MONITOR
- Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
- (2019) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells
- (2019) Youngjin Han et al. ONCOGENE
- PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
- (2019) Yilun Wu et al. Frontiers in Immunology
- Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges
- (2019) Muhammad Zaeem Noman et al. Cells
- Role of hypoxia in cancer therapy by regulating the tumor microenvironment
- (2019) Xinming Jing et al. Molecular Cancer
- Hypoxia modifies the polarization of macrophages and their inflammatory microenvironment, and inhibits malignant behavior in cancer cells
- (2019) Xixian Ke et al. Oncology Letters
- Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer
- (2018) Sofia C. Nunes et al. BMC EVOLUTIONARY BIOLOGY
- Scutellaria baicalensis targets the hypoxia-inducible factor-1α and enhances cisplatin efficacy in ovarian cancer
- (2018) Imran Hussain et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
- (2018) Willemien J. van Driel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins
- (2018) Kalpana Deepa Priya Dorayappan et al. ONCOGENE
- Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC
- (2018) Joel P. Joseph et al. ORAL ONCOLOGY
- The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment
- (2018) Salem Chouaib et al. Wspolczesna Onkologia-Contemporary Oncology
- Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429
- (2018) Qinglong Guo et al. Cell Death & Disease
- Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity
- (2018) Sofia C. Nunes et al. Scientific Reports
- Development of PARP and Immune-Checkpoint Inhibitor Combinations
- (2018) Ross A Stewart et al. CANCER RESEARCH
- Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
- (2018) Ignace Vergote et al. LANCET ONCOLOGY
- Contribution of FPR and TLR9 to hypoxia-induced chemoresistance of ovarian cancer cells
- (2018) Yongqing Cai et al. OncoTargets and Therapy
- A 3D microvascular network model to study the impact of hypoxia on the extravasation potential of breast cell lines
- (2018) Jiho Song et al. Scientific Reports
- A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer
- (2017) Bryan Oronsky et al. MEDICAL ONCOLOGY
- Tumour vessel normalization takes centre stage
- (2017) Megan Cully NATURE REVIEWS DRUG DISCOVERY
- miR-199a modulates cisplatin resistance in ovarian cancer by targeting Hif1α
- (2017) Xue Feng et al. OncoTargets and Therapy
- The role of hypoxia on the acquisition of epithelial-mesenchymal transition and cancer stemness: a possible link to epigenetic regulation
- (2017) Chang Dong Yeo et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
- (2017) et al. JAMA Oncology
- Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – A review
- (2017) Ahmed M. Al-Abd et al. Journal of Advanced Research
- Endothelial precursor cell-based therapy to target the pathologic angiogenesis and compensate tumor hypoxia
- (2016) Guillaume Collet et al. CANCER LETTERS
- Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism
- (2016) Zhihong Ai et al. CANCER LETTERS
- FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal
- (2016) Monika Haemmerle et al. JOURNAL OF CLINICAL INVESTIGATION
- Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Alexi A. Wright et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
- (2016) John K. Chan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoxia-inducible factor 1 alpha is required for the tumourigenic and aggressive phenotype associated with Rab25 expression in ovarian cancer
- (2016) Natividad Gomez-Roman et al. Oncotarget
- Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer
- (2015) Lynda M. McEvoy et al. BMC CANCER
- Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy
- (2015) MICHAL PASTOREK et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines
- (2015) Scott W Malm et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
- (2015) Sean Kehoe et al. LANCET
- Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer
- (2015) R. A. Previs et al. MOLECULAR CANCER THERAPEUTICS
- Modulation of Cell Metabolic Pathways and Oxidative Stress Signaling Contribute to Acquired Melphalan Resistance in Multiple Myeloma Cells
- (2015) Kamila Anna Zub et al. PLoS One
- Review Hypoxia-shaped vascular niche for cancer stem cells
- (2015) Guillaume Collet et al. Wspolczesna Onkologia-Contemporary Oncology
- Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival
- (2015) Yasuaki Amano et al. Oncotarget
- Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
- (2015) Nirmala Chandralega Kampan et al. Biomed Research International
- The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways
- (2015) Boh-Ram Kim et al. Oncotarget
- SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α
- (2015) Qilin Ao et al. Scientific Reports
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors
- (2014) Diego O. Croci et al. CELL
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
- (2014) Sandro Pignata et al. LANCET ONCOLOGY
- Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment
- (2013) Claudine Kieda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
- (2013) Noriyuki Katsumata et al. LANCET ONCOLOGY
- Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth
- (2013) G. Collet et al. MOLECULAR CANCER THERAPEUTICS
- Generation of cancer stem-like cells through the formation of polyploid giant cancer cells
- (2013) S Zhang et al. ONCOGENE
- Human erythropoietin increases the pro-angiogenic potential of A2780 ovarian adenocarcinoma cells under hypoxic conditions
- (2013) JÁN KRIŠKA et al. ONCOLOGY REPORTS
- Emblica officinalis Extract Induces Autophagy and Inhibits Human Ovarian Cancer Cell Proliferation, Angiogenesis, Growth of Mouse Xenograft Tumors
- (2013) Alok De et al. PLoS One
- The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness
- (2012) Bin Bao et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells
- (2012) E. F. Tewalt et al. BLOOD
- Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells
- (2012) Tsuyoshi Ohta et al. CANCER BIOLOGY & THERAPY
- HIF-mediated endothelial response during cancer progression
- (2012) Colin E. Evans et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology
- (2012) S. Goel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypoxia control to normalize pathologic angiogenesis: Potential role for endothelial precursor cells and miRNAs regulation
- (2012) Guillaume Collet et al. VASCULAR PHARMACOLOGY
- Lymphatic endothelial cells - key players in regulation of tolerance and immunity
- (2012) Eric F. Tewalt et al. Frontiers in Immunology
- Recent progress in the diagnosis and treatment of ovarian cancer
- (2011) Danijela Jelovac et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α
- (2011) Wenjing Su et al. CANCER LETTERS
- Cancer stem cells and angiogenesis
- (2011) Yue Zhao et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells
- (2011) Liisa Laatio et al. TUMOR BIOLOGY
- Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
- (2010) William M. Merritt et al. CANCER BIOLOGY & THERAPY
- Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer
- (2010) Kan INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer
- (2010) Johanna Chiche et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- RON and Cisplatin Resistance in Ovarian Cancer Cell Lines
- (2010) Silvia Prislei et al. ONCOLOGY RESEARCH
- Effects of HIF-1 and HIF2 on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts
- (2010) Swethajit Biswas et al. Journal of Oncology
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
- (2009) Andreas du Bois et al. CANCER
- Hypoxia induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator of transcription 3
- (2009) Karuppaiyah Selvendiran et al. INTERNATIONAL JOURNAL OF CANCER
- Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1α
- (2009) Lei Huang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Severe hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression
- (2009) Pedro C Lara et al. Radiation Oncology
- Identifying symptoms of ovarian cancer: a qualitative and quantitative study
- (2008) CR Bankhead et al. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1alpha) expression in serous ovarian cancer: an immunohistochemical study
- (2008) Alexandros Daponte et al. BMC CANCER
- Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
- (2008) William G. Kaelin et al. MOLECULAR CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started